Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK Chemical Structure

Molecular Weight(MW): 467.49

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Size Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A) LAN5 cells were untreated (top panels) or treated with 50 µM of the caspase inhibitor Z-VAD-FMK (bottom panels). Cells were co-treated with nothing (No Rx), 1 µM GSK-J4, or 1 µM venetoclax for 48 hours and assayed for apoptosis by flow cytometry.

    Science, 2018, 10(441), doi: 10.1126/scitranslmed.aao4680. Z-VAD-FMK purchased from Selleck.

    After treatment with 1.5 g/l matrine in the presence or absence of 10 nM Baf A1 or 20 nM rapamycin or 10 lM z-VAD-FMK (zVAD) for 24 hrs, the cell viability was measured by CCK-8 assay. Results were expressed as mean±S.E.M. representing at least three independent experiments. *P < 0.05, versus matrine alone group.

    J Cell Mol Med, 2017, 21(6):1171-1181. Z-VAD-FMK purchased from Selleck.

  • (A and B) Western blot analysis examining the effect of zVAD-fmk on the icaritin-induced apoptosis. The caspase inhibitor zVAD-fmk could significantly decrease the icaritin-induced cleaved caspase-3 expression. β-Actin protein levels indicate that an equal amount of protein was loaded into each lane.n=3. Mean±SD. bP<0.05, compared to the control group. eP<0.05, compared to the icaritin-treated group.

    Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck.

    Active caspase-3 expression analysis. SW1116 cells were treated with ZBH-1205, CPT-11 and SN38 at 25 μmol/L for 48 h, in the presence or absence of Z-VAD-FMK (50 μmol/L, 1 h ahead of time). *P= 0.0345. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). E: Cell cycle analysis. F: Apoptosis analysis. #P=0.0259. Z-VAD-FMK(-) vs. Z-VAD-FMK(+). ALL experiments were repeated three times.

    Arch Biochem Biophys, 2016, 604:74-85.. Z-VAD-FMK purchased from Selleck.

  • Effect on the RAS of CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk treatments administered 5 or 12 days after C26 inoculation and control groups. Western blot analysis of ATF2 and pATF2. CP, ZP and UP were treated for 5 days; CT, ZT, UT and CC were treated for 12 days. CFZ (CP), z-VAD-fmk (ZP), CFZ + z-VAD-fmk (UP), PBS only (CC), healthy control (HC).

    Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck.

Purity & Quality Control

Choose Selective Caspase Inhibitors

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Features A key compound for apoptosis studies.
Targets
Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro

Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
GC1a M1i2bGFxd3C2b4Ppd{BCe3OjeR?= MojKOVDPxE1? NVPqbnA3OjSq NGfOdmFqdmSrY3H0[ZMh[SCycn;0[YN1cX[nIHXm[oVkfCCjZ3HpcpN1KGW2b4Dvd4ll\Q>? MoPGNlYyPjlyN{W=
HGL5 MXLBdI9xfG:|aYOgRZN{[Xl? MmK0OVDPxE1? MnztNlRp M{TBSYlv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRm M3n5TlI3OTZ7MEe1
HepG2 M{fD[GFxd3C2b4Ppd{BCe3OjeR?= MViyNO69VQ>? NHTSWFUycA>? MmHMZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=> NVvSVIRwOjZzNkS3PVU>
BEL-7402 NGi1ZXVCeG:ydH;zbZMhSXO|YYm= NWHPR|BmOjEQvF2= M2fCW|Fp NWTKfWxn[XS2ZX71ZZRm\CC2aHWgZZBweHSxdHnjJIlv\HWldHnvckBw\iCLSVmtNVDDqA>? MUGyOlE3PDd7NR?=
CEF MnHMT4lv[XOnIFHzd4F6 NYTNZpV{OCx|Mzy2O{wyODEQvF2= NFvlVo4yPW2rbh?= M{jyS4Rwf25vcnXneYxifGW|IGDSJIVvgnmvZTDhZ5Rqfmm2eTD0c{A1OO,:hTDheEAyODEQvF2= M1LrcVI3OTB{M{O5
SP2/0 MXLBdI9xfG:|aYOgRZN{[Xl? MW[xNFDPxE1? NEmxe5kycA>? M3n1PGROW09? NYHjXoxx[myxY3vzJJRp\SCjcH;weI9{cXNib3[gV3AzNzBiY3XscJM> NGHwUZAzPjB5NEezNi=>
HUVEC-2c M1Kxb2Fxd3C2b4Ppd{BCe3OjeR?= MXq1NO69VQ>? MUK2bC=> M4nSfIRm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6 MVyyOlAzOTd{OR?=
U1 MnPuRZBweHSxc3nzJGF{e2G7 NVLsV2ZkOC1zMEFOwG0> MUSybC=> MU\y[YR2[2W|IHTyeYcucW6mdXPl[EBieG:ydH;zbZMh[W6mIIP1ZpNmeXWnboSgTGlXNTFicnXwcIlk[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV:yOVk5ODl2Mh?=
ACH-2 MnrtRZBweHSxc3nzJGF{e2G7 MnvFNE0zODEQvF2= MnH3Nog> NHfpT|hz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml7pNlU6QDB7NEK=
U1 MWHLbY5ie2ViQYPzZZk> MkfzNVAx|ryP MoPlNog> NV7qOmpbcW6qaXLpeJMh[2G|cHHz[U0{ M3TkUlI2QThyOUSy
A549/V16 NEf4fVNCeG:ydH;zbZMhSXO|YYm= MoLBOVDPxE1? MYexbC=> NH7Bd2xz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= NFK2bmkzPTl2NkCzNy=>
SGN NX;neWlDSXCxcITvd4l{KEG|c3H5 M3jYZlIxdU1? M2S3SlQ5cA>? NH\rb2Np[XNibn:gbY5ndHWnbnPlJI9vKEGLRjygZ4FteGGrbjDlfJBz\XO|aX;uJI9zKGOnbHygZZBweHSxc3nz NVWzT5REOjV6N{S2N|M>
HCT116  M3i2UGFxd3C2b4Ppd{BCe3OjeR?= M3i5[|Ux|ryP M3nGflJp NX3UZmZ3cW6qaXLpeJMhfGinIHPlcIwh\GWjdHigbY5lfWOnZDDifUBFTF[S NXLpfYJyOjV6Nki4NVg>
DTK-SME M4rITWFxd3C2b4Ppd{BCe3OjeR?= NFO4SnI2OM7:TR?= NWrrOGs2Omh? NFm2W4hFVVOR MWjwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHL1dIl3[WOjaX7l NFTtUnczPTh2M{i5Oy=>
HL-60 MonRRZBweHSxc3nzJGF{e2G7 MXu1NO69VQ>? NHrB[YM1QGh? NX3sTINYemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB? MmHCNlU5OjRyNEO=
U937 NHXPRYtCeG:ydH;zbZMhSXO|YYm= NVLwOmZIPTEQvF2= M{TGVVQ5cA>? Mk\kdoVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA> Mk\YNlU5OjRyNEO=
A549 NFfQbmRCeG:ydH;zbZMhSXO|YYm= NWPGPHFiOjBizszN NYLOU3hVOjSq M1mwcJJm\HWlZYOgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhUE[FUDD0doVifG2nboS= MWOyOVc6PDF2OR?=
HeLa NXTyOXNVSXCxcITvd4l{KEG|c3H5 NFvycpEyOM7:TR?= M3PtO|Q5cA>? NWXGflJZ\GWlbHnu[ZMhfGinIILheIUhd2ZiYYDvdJRwe2m|IHTyZY1ifGmlYXzsfS=> MX[yOVc4OjV2NR?=
SGC-7901 NUDaVol5SXCxcITvd4l{KEG|c3H5 Mly4NlDDqM7:TR?= Ml:3NYg> NFPNTZZqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JI95[WyrcHzheIlv NGfBUG0zPTd4N{C3Oi=>
MCF-7 M{S3b2Fxd3C2b4Ppd{BCe3OjeR?= MX[xNO69VQ>? M1[yU|Jp NEHQOWxqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JFND Moe2NlU4OjJzMUS=
A549 M4[0S2Fxd3C2b4Ppd{BCe3OjeR?= M3yyTlExKM7:TR?= MUiyOIg> NWnwTJZ1TE2VTx?= M3nE[5Bzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u Mni4NlU3QDN3Nki=
U87 M{fmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXv1W3E3PTEQvF2= Moi0NYg> NEPHTJBz\WOxdnXyd{Bk\WyuIHfyc5d1cCCocn;tJHROYiC2cnXheI1mdnR? MnH4NlU3QDF4Nki=
Neocortical Neuron MUPO[ZVzd3SxeHnjbZR6KEG|c3H5 NF7tPVkyODEQvF2= M3\uPFFp NULYU|hu[W62YXfvcol7\XNiSH;pZY1q\GViQT3JcoR2[2WmIF7leZJwfG:6aXPpeJk> M3m4NFI2Pjd3MECx
Primary human placental cytotrophoblasts MX;BdI9xfG:|aYOgRZN{[Xl? MX[zNO69VQ>? NV7W[JJtOjSq NFK3RVZFVVOR M3XoTZJmfmW{c3XzJJRp\SCrbnjpZol1cW:wIH;mJFEy|rJvSGPENkBjgSC2cnnjcI9{[W8EoB?= MXGyOVY1OjV7Mh?=
MM Mk\VRZBweHSxc3nzJGF{e2G7 MoXXOVDPxE1? NWPXOYk2OjCvaX6= M4G0R5BienSueTDpcohq[mm2czDTTGsucW6mdXPl[EAh[2WubDDk[YF1cA>? MX2yOVU{ODB7OB?=
DLD1 NGKwcplCeG:ydH;zbZMhSXO|YYm= MnfrNlDDqM7:TR?= MUmxbC=> NHXzd4Jx[XK2bImgdoV3\XK|ZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGfTVFE> MkPBNlU2OjR{NE[=
MDA-MB-231 MWLDfZRwfG:6aXPpeJkhSXO|YYm= NUe0PIc4OTEQvF2= MV2xbC=> MlPGZZVodWWwdIOgZ4VtdCCmZXH0bEBi\nSncjDDTHVCKHS{ZXH0cYVvfA>? NIG1OZgzPTV{MUWwNS=>
MKN28 M3\QNWFxd3C2b4Ppd{BCe3OjeR?= MljRNVDPxE1? MYOzNI1qdg>? Mo\OSG1UVw>? MVjpcohq[mm2czDUUmYu|rFicHz1d{BEUFhvaX7keYNm\CCjcH;weI9{cXN? M3njflI2PTF|OU[w
HL-60 Mn3zR5l1d3SxeHnjbZR6KEG|c3H5 MmruNVAx|ryP MVSxbC=> M2qxeGROW09? MmnoxsBqdXC{b4\ld{B3cWGkaXzpeJkhd2ZiVFPORZMufHKnYYTl[EBk\Wyucx?= NWPWfVlXOjV3MEK5N|I>
AGS NGflfmtCeG:ydH;zbZMhSXO|YYm= NYrX[HFMOTEQvF2= NWnXdlVVOWh? NXn6Z5NoeHKndnXueJMh[3W{Y4XtbY4ucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID24MEBidmRiLUmgdJJwfGWrboO= MmjnNlU1QTJ{MUS=
A549  MUTBdI9xfG:|aYOgRZN{[Xl? NUnJOJgzOTEQvF2= Ml\4NlRp MoLqZoxw[2u|IFTNRXMucW6mdXPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiYX7kJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp NUPZ[5JIOjV2M{S5PFk>
INS-1 MXfBdI9xfG:|aYOgRZN{[Xl? NF3yWGs2OM7:TR?= NW\4e3h1Pmh? NFnOe3BFVVOR MUjk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[g[YFzdHliYYDvdJRwfGmlIHPlcIx{yqB? NHPHR5MzPTR|MEi5Oy=>
Primary hepatocytes  NWDoNYpPSXCxcITvd4l{KEG|c3H5 MmXMOVDPxE1? MVyxPIg> NYTpNmhbcW6qaXLpeJMh[XCxcITvd4l{KG:oIHjldIF1d2O7dHXzJIlv\HWlZXSgZpkhSWO2IFSgZY5lKFSQRj5OtS=> NVuzN2Q{OjV2MEe1N|g>
L929-A  M4TqZmN6fG:2b4jpZ4l1gSCDc4PhfS=> NUTwbFlxOjEEoN88US=> Mnv6NlRp NUXZVWFncW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDj[YxtKGSnYYTo Mkn5NlU{QTh3NEC=
L929-N NGnWSHdEgXSxdH;4bYNqfHliQYPzZZk> NFTQfYUzOMLizszN NGnFW|czPGh? NUnYZWsx\W6qYX7j[ZMh\GWjdHigeoliKGG3dH;jdolv\SCWTldOtUBxem:mdXP0bY9v NH35UoozPTN7OEW0NC=>
Cytotoxicity Assay MmHER4VtdCCYaXHibYxqfHliQYPzZZk> NXn0U4dOOjEQvF2= MmPvOFhp NHrlcIRxemW4ZX70JG1JVURvaX7keYNm\CClZXzsJIRm[XSq MUKyOVM6OjFzNh?=
COS7 MXnLbY5ie2ViQYPzZZk> MlOxNVDPxE1? NIn1fFUzPGh? M1\4[4lv[3KnYYPld{Bk[XOyYYPlJFMwPyCjY4Tpeol1cWW| NGjO[3AzPTN6NECyOS=>
COS7 MlezRZBweHSxc3nzJGF{e2G7 NGXnbnAyOM7:TR?= MkDYOFhp M1vHd5BienSrYXzsfUBxemW4ZX70[YQhTkNzMEGtbY5lfWOnZDDj[YxtKGSnYYTo NXrTfGdIOjV|OESwNlU>
A375 MoLaRZBweHSxc3nzJGF{e2G7 M3ezPVMx|ryP M1PhRlJp Mmj4dJJmfmWwdIOgeIhmKGS{dXetbY5lfWOnZDDQRXJRKGOuZXH2ZYdm NHHPVGMzPTN5NkGxOS=>
A549 MmXXRZBweHSxc3nzJGF{e2G7 M{\lWFUx|ryP MXqyOIg> NGXZbnBz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFv MmrTNlU{PDl5OEG=
A549 NV:3WZhLSXCxcITvd4l{KEG|c3H5 NHjMe5UzNjVvMkZOwG0> NHrqVZYycA>? NFu0WlFl\WO{ZXHz[ZMhfGinIIDvdJVt[XSrb36gc4Yh[XCxcITveIlkKGOnbHzzJIRmeGWwZDDvckBkd26lZX70doF1cW:wcx?= M{TyclI2OzR{NEK3
 NBL-W-S  M37TR2Fxd3C2b4Ppd{BCe3OjeR?= M2HteVUx|ryP M3i0cFFp M4jwWYZ2dGy7IILld4N2\XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgS2FPXC14MTD0doVifG2nboS= MXKyOVMzOzJ{Mh?=
Caki-1  M1jjVGFxd3C2b4Ppd{BCe3OjeR?= M4LYdlQx|ryP NFLRPFU1QGh? MYny[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzz NIPyNpMzPTJ5OUG5NS=>
769-P M1PhNGFxd3C2b4Ppd{BCe3OjeR?= MYm0NO69VQ>? MkPpOFhp Mn63doVlfWOnczD0bIUhdnWvYnXyJI9nKEGwbnX4bY4hXi2yb4PpeIl3\SClZXzsdy=> NWPkbJJQOjV{N{mxPVE>
H9c2 NUK3RoJiSXCxcITvd4l{KEG|c3H5 MVq1NO69VQ>? M{TjbVFp NULIRXdicW6qaXLpeJMhTE:[LXnu[JVk\WRiY3HzdIF{\SB|IHHjeIl3[XSrb36gZpV1KG6xdDD0bIUhdG:|czDv[kBk\Wyucx?= NXfiVIZkOjV{OEO4NVk>
K562 NFqyWIhCeG:ydH;zbZMhSXO|YYm= MWS1NO69VQ>? M3XwTlRp M{n0d4lvcGmkaYTzJGpi[y2DLXnu[JVk\WRiY3XscEBieG:ydH;zbZM> NXjvd3E6OjV{NEG2NVk>
L929 MU\BdI9xfG:|aYOgRZN{[Xl? NUnDfVNlOTEQvF2= NVv2dlJWPmh? MofzbY5lfWOnczDu[YNzd3C2b4Ppd{B4cXSqIGTOSi=> MoTGNlUyQTV4NkC=
A549 MVjBdI9xfG:|aYOgRZN{[Xl? Mkf0NVDPxE1? NGeyd4I{cA>? MXzy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG= MWmyOVE3OTZ7OR?=
MCF-7 MlvORZBweHSxc3nzJGF{e2G7 NVr3WFNLOjEQvF2= MmTYNog> MV7k[YNz\WG|ZYOgT2RTNXOrUl7BMYlv\HWlZXSgZZBweHSxc3nz MorxNlUyQDJ{NEC=
OS M3\2UGFxd3C2b4Ppd{BCe3OjeR?= M4f2[|IxNzRyzszN M3\xOlczcA>? MnrGbY5pcWKrdIOgU3Mh[2WubDD2bYFjcWyrdImgdoVlfWO2aX;uJIJ6KEN4IHPldoFucWSn MnfoNlUyPTJ|OUm=
HUVECs M1nvXWFxd3C2b4Ppd{BCe3OjeR?= MoXxNVDPxE1? NImwWmozcA>? Mn;2xsBqdmirYnn0d{BieG:ydH;zbZMh[W6mIH\hZ4ltcXSjdHXzJIF2fG:yaHHnfUBqdiCGRV7WNk1qdm[nY4Tl[EBJXV[HQ4O= NITMOWwzPTF|OEewNy=>
EA.hy926 MmfkRZBweHSxc3nzJGF{e2G7 MX:xNO69VQ>? NGTMcJYzcA>? NHrtbGbDqGmwaHnibZR{KGGyb4D0c5NqeyCjbnSg[oFkcWyrdHH0[ZMh[XW2b4DoZYd6KGmwIFTFUnYzNWmwZnXjeIVlKEWDLnj5PVI3 NGXF[mQzPTF|OEewNy=>
Ebs NGHOUHZCeG:ydH;zbZMhSXO|YYm= M3v0fFExNTFyMN88US=> Mn7SNlRp NYnybI91yqCPTWTTJIdmdmW{YYTpc44hemG2ZTDk[YNz\WG|ZXSgZZMhfGinIHPvcoNmdnS{YYTpc44hd2Ziej3WRWQv\m2tIHnuZ5Jm[XOnZB?= MkDpNlUyOzR6MUe=
Jurkat MUXBdI9xfG:|aYOgRZN{[Xl? M2fMOVIx|ryP MVGyOIg> NVzJXmJyTE2VTx?= MljBdIFzfGmjbHz5JIlvcGmkaYSgZ4VtdCCmZXH0bEBw\iCMdYLrZZQh[2WubIOgbY5lfWOnZDDifUAyODB3OD3GOEBkd22kaX7l[EB4cXSqIG\QReKh NGXNOGozPTF{MEeyNy=>
K562 NXLCfXpySXCxcITvd4l{KEG|c3H5 MUKwMlEuOc7:TR?= MmrBNYg> M{\4SIlvcGmkaYTzJINt\WG4YXflJI9nKEiVUEmwJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUWyOVEyQTF6OB?=
IMR-32 NYnsTGdJSXCxcITvd4l{KEG|c3H5 M4m4[lQxyqEQvF5CpC=> MlPSNog> NYDzS3Y4\GWlcnXhd4UhcW5iYYDvdJRwfGmlIHPlcIx{KGOxbYDhdoVlKHSxIGStNkB1d3irbh?= M33MdlI2ODh2N{W1
RPMI 8226 M1y2WGFxd3C2b4Ppd{BCe3OjeR?= MWSxNFDPxE1? MWmxbC=> MkTwZYxud3O2IHPvcZBt\XSnbImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF? MnzCNlUxOzd6NUG=
U266  NX3BZYxDSXCxcITvd4l{KEG|c3H5 Mo\ZNVAx|ryP NGrpVpIycA>? NUj2foJbeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x NHjmWFMzPTB|N{i1NS=>
H929  Mn\LRZBweHSxc3nzJGF{e2G7 MkLVNVAx|ryP MnHXNYg> NULkXWRFeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2x MmnqNlUxOzd6NUG=
MM.1S  MV7BdI9xfG:|aYOgRZN{[Xl? NYPSSWZxOTByzszN MnrsNYg> NWHuO3p7\W[oaXPp[Y51dHlicILleoVvfHNic3;yZYZmdmmkLXnu[JVk\WRiY3XscEBl\WG2aDDjc41jcW6nIIfpeIghdmWlcn;zeIF1cW5vMR?= Mn;INlUxOzd6NUG=
C6 NXjKZoh{SXCxcITvd4l{KEG|c3H5 NISwVIw2OM7:TR?= NH:4bHo1QGh? M17jcZBz\X[nboTzJJRp\SCub4PzJI9nKGOnbHygeoli[mmuaYT5JINifXOnZDDifUBxemWpbnXuc4xwdmV? MVyyOVAyOzR5OR?=
AGS NYi3N|JbSXCxcITvd4l{KEG|c3H5 M1v0elUx|ryP NWnKdnB2OjSq M3\5XYFjd2yrc3jzJO6zNWyjcHHjbI9v\S2rbnT1Z4VlKGOnbHyg[IVifGhiYX7kJIlvcGmkaYTl[EBoem:5dHi= MXyyOVAxQTZ7OB?=
HeLa  MWjBdI9xfG:|aYOgRZN{[Xl? MmXGOFDPxE1? M3\GRVI1cA>? M3qy[4lvcGmkaYTzJJRp\SCrbnPy[YF{\WRiYYDvdJRwe2m|IHnu[JVk\WRiYomgd4lTVkZzMkG= NXvB[3F7OjR7Mki2PFU>
THP-1  NGixOYhCeG:ydH;zbZMhSXO|YYm= MYKxNO69VQ>? Mn\pNYg> MYfy[YR2[2W|IHHwc5B1d3OrczDpcoR2[2WmIHL5JGFNSS2VRGVCpC=> MnHJNlQ6OjN4NUO=
P815  M2TXfWFxd3C2b4Ppd{BCe3OjeR?= M1rydlExOCEEtV2= MnnMNVJp NX3yN2lSTE2VTx?= MX\pcohq[mm2czD2bZJ2ey2rbnT1Z4VlKGGyb4D0c5Nqew>? NULoNVFCOjR7MkOyO|M>
HCT116 MlTmRZBweHSxc3nzJGF{e2G7 MWeyNO69VQ>? NYjKOG5XOjSq NEHOPWli[nKxZ3H0[ZMhd2ZiVGGtbY5lfWOnZDDhdI9xfG:|aR?= NFzaZ4QzPDh7MES0PS=>
SW1116  NGPNbJdCeG:ydH;zbZMhSXO|YYm= NFzIW2EyOCEEtV2= MUexbC=> MofvSG1UVw>? M3jVfZJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= NHnsUlAzPDh5NEK4Oi=>
LOVO MnWzRZBweHSxc3nzJGF{e2G7 MojNNVAhyrWP M2j2Z|Fp NVzhd2o3TE2VTx?= M{C2UJJme3S{YXnud{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JIdm\mm2aX7pZkBxdHW|IHTlZ4l1[WKrbnW= M4PYbFI1QDd2Mki2
SNU449  NUj4PJhwSXCxcITvd4l{KEG|c3H5 M2\1OFIx|ryP NHjURmQ1QGh? MUXEUXNQ NVnlc5d6\GWlcnXhd4V{KG2rUj20OVEucW6mdXPl[EBieG:ydH;0bYM> MmLaNlQ5PDF4M{i=
Caco-2 M3LtXWFxd3C2b4Ppd{BCe3OjeR?= NWLnZ4NTPDEkgJpOwG0> NXm3bVR[PGh? NVzRUJBGeHKndnXueJMhW1RvNz3pcoR2[2WmIGrPMVEh[2ijbnfld{BidmRiVFXSJIRzd3B? NUny[I9sOjR6MkKxPFM>
macrophage M{\ENWNmdGxiVnnhZoltcXS7IFHzd4F6 M1;nSVAuOjByzszN MnPpNlRp M4\ucolv\HWlZYOgWG5HNSCjbnSgVolxOy2mZYDlcoRmdnRibnXjdo9xfG:|aYOgbY4hdWGlcn;wbIFo\Q>? MVyyOFc6QTV4NR?=
AGS  MYXBdI9xfG:|aYOgRZN{[Xl? MnfjNlDPxE1? MkHLNVJp NGXFS4lFVVOR NEDES2dz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIlvKHKnc4DvcpNmKHSxIITo[UBGfE:DYzDmdoFkfGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVeyOFc5QTdyMx?=
LCC9  NFHjUIdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M37hOVExOM7:TR?= M2nkWFVl NXPHU49K[myxY3vzJINmdGxiZHXheIghcW6mdXPl[EBjgSClb33ibY5ifGmxbjDMNVch[W6mIHPocI9zd3G3aX7l MVSyOFc5PTJ3Nh?=
U937  NF;0dJRv\WO{b4D0c5NqeyCDc4PhfS=> NWrkcoFLOTEEoN88US=> NEHqcHg{OMLibXnu MXzpcoR2[2W|IH7lZ5JweHSxc3nzJINwdWKrbnWge4l1cCCWTl[= MofiNlQ4PzN5NU[=
T cell NV3iPWNrS2WubDDwdo9tcW[ncnH0bY9vKGG|c3H5 M37EVlAuOTByzszN M{\KSVczcA>? NEHGcFNKSzVyPUewJO69VSxiaX7obYJqfHNiYX70bU1ETDNvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjDpckBRSk2Fcx?= NVrtZoZmOjR5Nki3NFc>
HeLa  M1TqcWFxd3C2b4Ppd{BCe3OjeR?= M1XOT|Ux|ryP NIPmZZM4Omh? Mn33SG1UVw>? MY\wdoV3\W62czDhdI9xfG:|aYOgbY5lfWOnZDDifUBkd22yb4Xu[JPDqDIkgKO1 NGXkbXUzPDd3NEe4Oi=>
HeLa  MVLBdI9xfG:|aYOgRZN{[Xl? M4[2PVExOM7:TR?= MX[yOIg> MULzeZBxemW|c3XzJJJifGVib3[gZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KG:4ZYLlfJBz\XO|aX;uJI9nKEd3OWOgc5IhTzdzUjDwNVUx\2y3ZXVCpC=> MojtNlQ4OjJ2Nki=
IEC-6  MXfBdI9xfG:|aYOgRZN{[Xl? M1izbVEx|ryP M2PZfFI1cA>? NXqzO4N5eHKndnXueJMhXGOmQT3pcoR2[2WmIHPhd5Bie2VvMzDjcIVifmGpZTDhcoQh|rJvY3H0[Y5qdiCmZXfyZYRifGmxbh?= NITMflUzPDdzMUW3NS=>
HCT116 NEfpPGlCeG:ydH;zbZMhSXO|YYm= MmXNNlDPxE1? NH:zXFEzPGh? M1HBVYlvcGmkaYTzJJRp\SClZXzsJIFxd3C2b4TpZ{BqdmS3Y3XkJIJ6KFmOVEKwOS=> MYiyOFcyOzhzMh?=
L02 MoTsRZBweHSxc3nzJGF{e2G7 NHWxRZIzOM7:TR?= MkW5NYg> M3ixe5Bz\X[nboTzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE2HSGC= MUeyOFcxPjR4MR?=
A375 NUPuS3JzSXCxcITvd4l{KEG|c3H5 NIDrbW8zOM7:TR?= M1jEV|I1cA>? NXHnUXE1emW4ZYLz[ZMh\GmlaYTybY5wdmViQj3pcoR2[2WmIHHwc5B1d3Orcx?= NVH5bm51OjR4OUmxNVE>
HDPC NYLL[WkxSXCxcITvd4l{KEG|c3H5 NUPkfoxzPTEEtV2= MljGNlRp Mm\ybY5pcWKrdIOgUm8ucW6mdXPl[EBieG:ydH;zbZM> NGjYfmkzPDZ|NEW5Ny=>
A549 MkHDRZBweHSxc3nzJGF{e2G7 MoD1OVDDvU1? NVTVO3RMOmh? MXvEUXNQ MoP6dJJmfmWwdIOgeIhmKGi7cH;kbZBtd2mmIFTORUBkd262ZX70JJBp[XOnIHnu[JVk\WRiYomgZ4VxcGGub3Podo9ucW5? M{HkU|I1PTh6MUO1
 BV-2 NHriVlNCeG:ydH;zbZMhSXO|YYm= MmezNlDPxE1? M4rRSlJp MlXsd5VxeHKnc4Pld{BWXi2rbnT1Z4VlKGOqcn;tZZRqdiCneITyeZNqd25iYX7kJIRqdGG2aX;uJI9nKHSqZTDueYNt\WG{IHXueoVtd3Cn MmG2NlQ2PThzMUi=
HT-29  MW\BdI9xfG:|aYOgRZN{[Xl? M3;uVFUx|ryP Mn[2OFhp M3rXRYJtd2OtczD0bIUh[XCxcITvd4l{KGmwZIXj[YQh[nlia3HlcZBn\XKxbB?= MorjNlQ2PDlzN{W=
A549 NHzuZ3NCeG:ydH;zbZMhSXO|YYm= NECwV4M2|ryP NIHaSHgzPGh? MnvQd5VxeHKnc4Pld{A3\cLiKFLLNVAxPDBrLXnu[JVk\WRiYYDvdJRwe2m|wrC= M{PUeVI1PTJ7OEex
MIA-PaCa-2 NHrifYtCeG:ydH;zbZMhSXO|YYm= NXzsVGNzOjSq NX;IUoNw[myxY3vzJINt\WG4YXflJI9nKGOjc4Dhd4UuOyCrbnT1Z4VlKGK7IHLveIghSS12NEO2OVQh[W6mIIDhZ4xqfGG6ZXy= NVnwTG1jOjR3MUC5PVI>
Caki-1 M3zXfmFxd3C2b4Ppd{BCe3OjeR?= MWWyNO69VQ>? NEP6eZkycA>? NF7YbY5qdmirYnn0d{BUS1BvaX7keYNm\CCjcH;weI9{cXN? NILNepYzPDVyNE[4NS=>
CLL MU\BdI9xfG:|aYOgRZN{[Xl? MXqyOe69VQ>? NYnCcZV4OWh? MnrSdIFzfGmjbHz5JIJtd2OtczDNUG4zOjN6LXnu[JVk\WRiY3XscEBieG:ydH;zbZM> Mlm2NlQ1Pjd4M{S=
SGC-7901 MYXBdI9xfG:|aYOgRZN{[Xl? MVmxNO69VQ>? NH\mZmwzPGh? NI\hfFBxem:vb4Tld{B1cGViQ1fJTU1qdmirYnn0[YQh[2WubDDndo94fGhiaX6gV2dENTd7MEGgZ4VtdHN? M3jDWlI1PDV2NEi4
k1735 NHflS2pCeG:ydH;zbZMhSXO|YYm= MkmwNlDjiIoQvH2= Mki5OIg> M1zBfIlvcGmkaYTzxsBU[Wyvb37lcIxiNWmwZIXj[YQh[XCxcITvd4l{ M3LHd|I1PDVzMUG2
HaCaT  M32xPGFxd3C2b4Ppd{BCe3OjeR?= NFfBc5cyODEQvF2= MmnBNYg> M2TzfoJtfW62czDVWmIucW6mdXPl[EBieG:ydH;zbZMhcW5iSHHDZXQh[2WubIO= MWKyOFM2Pjl7Nx?=
podocytes MU\BdI9xfG:|aYOgRZN{[Xl? NW\YWHlmOjByzszN M1nvOFZp NWftUoJocW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliMzy0MWRITQ>? MYSyOFM{Pzd5Nx?=
 KB NV\TdHhkSXCxcITvd4l{KEG|c3H5 NGq4Opk2OM7:TR?= MUiyOIg> MV;pcohq[mm2czDMbYNwNUFvaX7keYNm\CClYYPwZZNmNTNiYX7kJHBCWlBiYXP0bZZifGmxbh?= NF61dpAzPDN|N{S5Ni=>
 HepG2  MX3BdI9xfG:|aYOgRZN{[Xl? M1Wy[|Ex|ryP MVeyOIg> MljHdoVlfWOnczD2bY1mdnSrbjDjcIVifmGpZTDjZZV{\WRiYomgUHBU NH\XU28zPDN{NUixOi=>
fetal rat lung fibroblasts  M1rFbGtqdmG|ZTDBd5NigQ>? MkTjPFDPxE4EoB?= NE[4XHYycA>? NGXFW41qdmirYnn0d{BE[XOyYYPlMVMh[WO2aY\peJnDqA>? MnLTNlQ{OTRzM{W=
PDL fibroblasts MlTZT4lv[XOnIFHzd4F6 MoH1PFDPxE4EoB?= NFS4R4oycA>? MXvpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=> MlL3NlQ{OTRzM{W=
MB49 M1G4dWFxd3C2b4Ppd{BCe3OjeR?= M4LyXlIx|ryP MVKxbC=> M1HhW5JmfmW{c3XzJGNONWmwZIXj[YQh[2WubDDk[YF1cA>? NYHUeVFPOjR{OEK0N|M>
5637 MlrFRZBweHSxc3nzJGF{e2G7 MnXlNlDPxE1? MXGxbC=> MkDqdoV3\XK|ZYOgR20ucW6mdXPl[EBk\WyuIHTlZZRp NITEWlgzPDJ6MkSzNy=>
A549  MnTwRZBweHSxc3nzJGF{e2G7 NXnLbYtCOTByzszN NUC5b3RXPDiq MU\zeZBxemW|c3XzJJRp\SCjcH;weI9{cXNiY3H1d4VlKGK7IIDpdIVzcW6nwrC= NW\xfWVuOjR{N{KyNFE>
MCC-2 MlL1RZBweHSxc3nzJGF{e2G7 NE\vNIszOCEQvF2= M2qxOlZp NIfDV4lFVVOR MWXicI9kc3NiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5mKGGyb4D0c5NqeyClZXzsJIRm[XSq NXrnbFFOOjR{NkK2OVg>
ADF NVnLTnF{SXCxcITvd4l{KEG|c3H5 MkL5OFDPxE1? MWC2bC=> Mn\ZbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkh[2inbX;0bIVz[XC7IIDseZMhYm6FbEK= M2jrR|I1OjJ6MkOy
 U373  NWjiOpMzSXCxcITvd4l{KEG|c3H5 MXe0NO69VQ>? NVHIcnFjPmh? NIWwOYRqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSClaHXtc5Rp\XKjcImgdIx2eyCcblPsNi=> MlXaNlQzOjh{M{K=
RKO-HIPK2i NGDMOpJCeG:ydH;zbZMhSXO|YYm= M1vIeVQx|ryP M2PrdlZp M4Hoe4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yy NVnqNGZOOjR{MkiyN|I>
HEC-1B MVjBdI9xfG:|aYOgRZN{[Xl? MWWyNO69VQ>? M{DkU|Fp M{fr[5Jm\HWlZYOgWHAucW6mdXPl[EBieG:ydH;zbZPDqGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25 NHyxbJQzPDJzM{O1PC=>
4T1 NHfWVIpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGDoUoYzNjVvMUFOwG0> NYDrVZZjPGh? MYTEUXNQ MYXy[ZNkfWW|IITo[UBkgXSxdH;4bYNqfHlib3[gOHQyKGOnbHzzJIlv\HWlZXSgZpkhW1CGVDDpckBiKGOxbnPlcpRz[XSrb36g[IVx\W6mZX70JI1idm6nch?= Mn:5NlQzODZzNkG=
OS  NETHSXJCeG:ydH;zbZMhSXO|YYm= NGXO[YszOM7:TR?= M4TxTFRp MoHzbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IGDEWC=> NH3ySlAzPDJyNEmzOy=>
RPE NGCxOnJCeG:ydH;zbZMhSXO|YYm= Mn\PNVAx|ryP NYrieVljPDiq M2noR5BienSrYXzsfUBqdmirYnn0d{B1cGViY3HsdIFqdi1zIHHu[EAuOiCjY4TpeoF1cW:wIHHzJJdmdGxiYYOgeIhmKGOjc4Dhd4Uh[WO2aY\heIlwdg>? NVzKPVkxOjR{MEKwOVI>
UD29a NY\NdFlMSXCxcITvd4l{KEG|c3H5 Mo\NOVDPxE1? NWSzbmdROjSq MXLpcohq[mm2czD0bIUh[2WubDDk[YF1cCClYYXz[YQh[nliTmXUNy=> NUHyN5ZIOjRzOUC1O|Q>
SH-SY5Y  MoTmRZBweHSxc3nzJGF{e2G7 MkLrNVDPxE1? MVuyOIg> MYTheJRmdnWjdHXzJINie3Cjc3WgZYN1cX[jdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JGhPTS1{RFe= M1y2WlI1OTR3NE[z
HeLa  M1\R[GFxd3C2b4Ppd{BCe3OjeR?= MX6xNE8zOM7:TR?= NImxVFgzPGh? NVK0[odRcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJJRp\SCvYXrvdol1gSCxZjD0bIUhdWWvYnXyd{Bw\iC2aHWgZ4F{eGG|ZT3mZY1qdHl? NY\h[pMxOjRzM{eyOlY>
SCCVII  M4jNWWFxd3C2b4Ppd{BCe3OjeR?= NYq4[mxnOjYQvF2= NWT1UGFuOWh? MlLxbY5pcWKrdIOgeIhmKGOnbHygb4ltdGmwZzDh[pRmeiCmYYPheIlvcWJ? MVGyOFEzPjR4NB?=
RAW 264.7 MmK2RZBweHSxc3nzJGF{e2G7 MV:yNO69VQ>? MXexPIg> NXGzTnhPcW6lcnXhd4V{KEyFMz3JTU/Pui2jY4TpckBz[XSrbzDjc41x[XKnZDD0c{BGS1SYLV3PV{B1emWjdH3lcpQhd26ueR?= NXLa[lNtOjRzMU[3NFc>
A549  M{HKcWFxd3C2b4Ppd{BCe3OjeR?= MkPlNk42|ryP M4jrPVI1cA>? NFex[mVl\WO{ZXHz[ZMhd3KrZH;ubY4ucW6mdXPl[EBifXSxcHjh[5kh[XNid3XscEBidmRiTH;zd{Bw\iEQlN-IcUBidHOxIH;jZ5VzemWmIHT1dolv\yCjdYTvdIhi\2mlIIDyc4Nme3N? NGfSS2ozPDFyMkWyNi=>
UM-SCC-10A  MV;BdI9xfG:|aYOgRZN{[Xl? MnOwOVDDvU1? MXKybC=> NVKzVJNRemWmdXPld{BieG:ydH;zbZMhcW6mdXPl[EBjgSCqaXfoMYRwe2ViaYPvZYxidnSxbHHjeI9v\Q>? M3XUV|I1ODl6N{Wz
BGC-823 MWrBdI9xfG:|aYOgRZN{[Xl? NFr2cZgyOCEQvF2= M33sSlI1cA>? MWfy[YR2[2W|IITleJJidmS{aX7lMYlv\HWlZXSgZZBweHSxc3nzxsA> NIjpcoozPDB7OEWxNS=>
Nalm-6  MW\BdI9xfG:|aYOgRZN{[Xl? M4L0OlIx|ryP M3rXUVRp MnnDbY5pcWKrdIOgZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTNiYXP0bZZifGmxbjDhcoQhWEGUUD2xJINt\WG4YXfl NHfNOWIzPDB|OUm2Oy=>
KHOS  MWLBdI9xfG:|aYOgRZN{[Xl? NGCzOm01OM7:TR?= Mm\RNlRp MlLHZoxw[2u|IITo[UBqdmO{ZXHz[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHnu[JVk\WRiYomgRmJOTDQEoB?= NF;KVlEzPDB{NUO2NS=>
G292 MmnERZBweHSxc3nzJGF{e2G7 NVKxOo1[PDEQvF2= M3XRflI1cA>? NIHX[XNjdG:la4OgeIhmKGmwY4LlZZNm\CClbHXheoFo\SCxZjDjZZNx[XOnLUOgZY5lKFCDUmCgbY5lfWOnZDDifUBDSk2GM9Mg NFL2[3YzPDB{NUO2NS=>
MG-63 NGT2S2pCeG:ydH;zbZMhSXO|YYm= M4X0elQx|ryP MXKyOIg> M3vEcoJtd2OtczD0bIUhcW6lcnXhd4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDhcoQhWEGUUDDpcoR2[2WmIHL5JGJDVUR|wrC= M{DlPFI1ODJ3M{[x
EBV-transformed B cells M4H3SWFxd3C2b4Ppd{BCe3OjeR?= M{XGd|Ix|ryP NGLSfHYzcA>? NVrlSHlQTE2VTx?= M{HWTYJtd2OtczDhcpRqNUOGOECgZY5lKGGwdHmtR2Q5PiCjboTpZo9lgS2rbnT1Z4VlKGGyb4D0c5Nqew>? Mlf0NlQxODh4Mki=
IM-9 B Mn;QRZBweHSxc3nzJGF{e2G7 M{LSTVIx|ryP NUPmZ25xOmh? MUnEUXNQ Ml[1Zoxw[2u|IHHueIkuS0R6MDDhcoQh[W62aT3DSFg3KGGwdHnic4R6NWmwZIXj[YQh[XCxcITvd4l{ MlLSNlQxODh4Mki=
CNE1 NFv2PYNCeG:ydH;zbZMhSXO|YYm= M3XCTlIx|ryP NHfSWYk1QGh? NWTYb3J4[myxY3vzJGxMNUFvaX7keYNm\CCjcH;weI9{cXN? M1zqUFI{QTh3MEK5
CNE2 NUG4R5Y3SXCxcITvd4l{KEG|c3H5 NWKwdWVnOjEQvF2= MonqOFhp MWnicI9kc3NiTFutRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> NFL4fWYzOzl6NUCyPS=>
HL-60 M{niOWFxd3C2b4Ppd{BCe3OjeR?= MnPzOVDDvU1? NUDab2lUOWh? MYLEUXNQ MWrpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBDSTF2NR?= MYCyN|k1QDd3MR?=
L929 Mlv3RZBweHSxc3nzJGF{e2G7 M1LkNlEvOjYkgKO1xsDPxE4EoB?= M{fjNVI1cA>? NYfXN29E[XWpbXXueJMhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7 NYXrUJpiOjN7NEG3Olk>
Jurkat MknuR4VtdCCYaXHibYxqfHliQYPzZZk> M{WzRlLPxE1? MXm0bC=> MYry[ZZmenOnczDndo94fGhiaX7obYJqfGmxbjDhcoQh|rJvY3H0[Y5qdiCmZXPy[YF{\SCkeTDIV{1CW0F? NHfhTIszOzh7NkC2NS=>
RAW264.7  MofuRZBweHSxc3nzJGF{e2G7 M2XNVVExKM7:TR?= Ml\aNlRp Mlrs[IVkemWjc3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDHRS=> NULPW2MxOjN6MkCyNFM>
A431  NXPHNmc4U2mwYYPlJGF{e2G7 NHi4[5A1OM7:TR?= M{LBPVJp MXHicI9kc3NiZnnz[ZRqdi2rbnT1Z4VlKGOuZXH2ZYdmKG:oIHPhd5Bie2W|IHHu[EBRSVKS MkfJNlM5ODByNUi=
Jurkat NEPIfJBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXj2T5N1OjVvMUCw{txO NXPhcHVRPmh? NYX0VmxkcW6qaXLpeJMhgi2IQT3DUWsucW6mdXPl[EBk\WyuIHTlZZRp MWKyN|k{OzV|Mh?=
COS-7  MYLGeY5kfGmxbjDBd5NigQ>? NETUWIE2OML3TR?= NXHKco5POjSq Mmj2ZYZn\WO2czD0bIUheHKxY3Xzd4lv\yCxZjDBWG4yeyC5aYToJJBwdHmTIITyZYN1ew>? M3rxTVI{QTN|MkC4
CAL27 M4XYNGFxd3C2b4Ppd{BCe3OjeR?= M3n0fVExKM7:TR?= NFfFdo4zcA>? MYDzeZBxemW|c3XzJGN2ei2QUIOtdoVlfWOnZDD2bYFjcWyrdImgZpkhfXBidH:gPVAm Mo\sNlM6OTd|OU[=
THP-1  NXvlV|VwSXCxcITvd4l{KEG|c3H5 MnjZNVAuPTEQvF2= MkDPNog> NXrVZZhOcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nlidILpdJRwdGmmZR?= M4\1dFI{QTByMkm5
K562 MUPBdI9xfG:|aYOgRZN{[Xl? NXu1VIJGOjEQvF2= NFrVVmc1QGh? NUfYU4w3cW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliND3NWS=> MlexNlM5PzZ6Mk[=
HL-60 MVzBdI9xfG:|aYOgRZN{[Xl? NVXRfpI3OTByzszN NHuxdpgzPGh? MXXpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBi[mmndHHu[UBlcXSncoDlcoV{yqB? NVm1U3BuOjN6NkW3O|g>
HeLa  Mkf0RZBweHSxc3nzJGF{e2G7 NEPhTHczOM7:TR?= NUn6Nmt1Omh? MYjpcohq[mm2czDEUW1RKGmwZIXj[YQh[XCxcITvd4l{ M{LTXVI{QDZ|OU[2
U251 NV\CSFFWSXCxcITvd4l{KEG|c3H5 MVuyNO69VQ>? NVrEeo9EOjSq MWTpcohq[mm2czDjZZN1cWOrbjDpcoR2[2WmIFeyM20heGijc3WgZZJz\XO2IHHu[EBieG:ydH;zbZM> NELXSVQzOzhzNkixOi=>
HL-60 MWXBdI9xfG:|aYOgRZN{[Xl? Mn35OVDDvU1? Mlr2OIg> MkOwZoxw[2u|IITo[UBkdGWjdnHn[UBw\iClYYPwZZNmNTNuID25MEBidmRiUFHSVEBqdmS3Y3XkJIJ6KD[| NEfwVoMzOzhyNEewOi=>
Ec-109 M{HzcmFxd3C2b4Ppd{BCe3OjeR?= Mnm0NVAh|ryP MU[0PIg> NWPUeGM1emWycnXzd4V{KFCHLX3l[IlifGWmIFXjMVExQSClZXzsJIFxd3C2b4Ppdy=> M4nDOlI{Pzh{NkSx
RKO MonPR4VtdCCYaXHibYxqfHliQYPzZZk> M2LHeVExKM7:TR?= M2PSWlI1cA>? M4fKdIlvcGmkaYTzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSClYYXz[YQh[nliRFHC MnTWNlM4PThyNkS=
T98G NIrhZ4dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXOxMVExOM7:TR?= Mn;1NlRp M{W3SolueHKxdnXzJINmdGxidnnhZoltcXS7IHPveJJm[XSvZX70JJdqfGhiVGO= NU\mboxUOjN5NkmyO|U>
Jurkat NVKwfWdXS2WubDDWbYFjcWyrdImgRZN{[Xl? MlHPNVAxNTJyMN88US=> MnGzNlRp M1vmW4lvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?= NEXhW4IzOzd|MkS4NS=>
Molt-3  NI\4bZZCeG:ydH;zbZMhSXO|YYm= NVLKcHpPPTEQvF2= NGjRPVczcA>? NVPMSplNemWmdXPld{Bu\WyjdH;ubY4ucW6mdXPl[EBieG:ydH;zbZM> M4DkUlI{PzJ3MEGz
hMSC12 NWHoRY17SXCxcITvd4l{KEG|c3H5 NVrQfGQ3OTByzszN NGnQV5M1\A>? MUDpcohq[mm2czDvd5Rmd2enbnnjJIN2dHS3cnWtbY5lfWOnZDDj[YxtKGSnYYToJIFv\CClYXzjbYZq[2G2aX;u NHuybG4zOzZ3N{iyNi=>
HM7  NFm4[5hCeG:ydH;zbZMhSXO|YYm= MnzCNlDPxE4EoB?= NGm1UnMycA>? NV3nbVZ4[myxY3vzJIFxcWO3bHHy[Y4hSSCjY3X0ZZRmNWmwZIXj[YQh[2G|cHHz[U0{KGGldHn2ZZRqd25iYX7kJHBCWlBiY3zlZZZi\2V? NGT3SoczOzV6M{SxNi=>
Hep-2  M{P5OmFxd3C2b4Ppd{BCe3OjeR?= MYmyNO69VcLi NWnURm8{OjSq Mn74SG1UVw>? M3nhRYFtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnu NITtZWszOzV6MECzNi=>
HSCs M1HCfGFxd3C2b4Ppd{BCe3OjeR?= NXf3WIlMPTEQvF2= NULENWNzOjSq NH7tbFVFVVOR MVjpcohq[mm2czDubYxwfGmwaXKtbY5lfWOnZDDEUmEh\GGvYXflJIlv\GmlYYTl[EBjgSCSQWLQJINt\WG4YXfl M{HST|I{PDl7OEe0
HL-60  NX;1TJR1S3m2b4TvfIlkcXS7IFHzd4F6 MonBNlDPxE4EoB?= M4PLTVI1cA>? MXTy[YR2[2W|IITo[UBkgXSxdH;4bYMh\W[oZXP0JI9nKEW{eUW= M1roZVI{PDl2NEiw
HA M1WzOGFxd3C2b4Ppd{BCe3OjeR?= M3jkN|Ux|ryP M2PVdlI1cA>? MVzzeZBxemW|c3XzJJRp\SClbHXheoFo\SCxZjDQRXJRKGGwZDDjZZNx[XOnLUOsJE04NCCjbnSgMVkhcW6mdXPl[EBjgSCkb4L0[ZpwdWmkL2PBTGE> MW[yN|Q4PTl3Nh?=
C666-1 M3S1c2Fxd3C2b4Ppd{BCe3OjeR?= NUnxcFUxPTEQvF2= NH3JRWczPGh? NWXRPZhVe3WycILld5NmeyC2aHWgZ4xm[X[jZ3Wgc4YhWEGUUDDhcoQh[2G|cHHz[U0{NCBvNzygZY5lKC17IHnu[JVk\WRiYomgZo9zfGW8b33pZk9USUiD M3HlN|I{PDd3OUW2
Hepa1-6 NI[5XI1CeG:ydH;zbZMhSXO|YYm= NH24PJY2OM7:TR?= M2\zXlJp M1fzeIlvcGmkaYTzJIN2emO3bXnuJIFv\CC{ZYP2[ZJifHKxbD3pcoR2[2WmIHHwc5B1d3Orcx?= NF;KZ|UzOzR2Nke1Ny=>
PLC/PRF/5c NUjP[IlvSXCxcITvd4l{KEG|c3H5 MlvuOVDPxE1? NXPMWXIzOWh? MXvwdoV3\W62czDhdI9xfG:|aYOgeJJq\2encnXkJIJ6KEOLTh?= NYDIeHhtOjN2M{i4NlQ>
HCT116 NF7IfoNCeG:ydH;zbZMhSXO|YYm= Ml;0NVAx|ryP NEjQfHoyNjWq NIXyUIRqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh? M{PnXFI{PzR2M{Wz
HCEC Ml7RSpVv[3Srb36gRZN{[Xl? NYPoV4ZMPTEQvF2= MXu3Nog> MWnEUXNQ MkezdoV{fG:{ZYOgc4YhfGinIH7vdo1idCCKQ1XDJJBp\W6xdInw[S=> NUP3R2k3OjN5NEKwNVE>
Primary rat cerebral cortical neurons M1q1WmFxd3C2b4Ppd{BCe3OjeR?= NHjlPG8yODEQvF2= NF61TYcycA>? NWDIXoRmeHKndnXueJMhS2RvaX7keYNm\CCjcH;weI9{cXNiYX7kJINmdGxiZHXheIg> Ml7hNlM4PDF|MUe=
MDA-MB-231  MWnBdI9xfG:|aYOgRZN{[Xl? MnrwNlXPxE1? Ml7RNlRp MUXhZpJw\2G2ZYOgZ5l1d3SxeHnjbZR6KGGwZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMh[W6mIGDBVnAhcW6mdXPl[EBjgSCUZ{O= MXSyOVM{PzV2NB?=
NLRP3-Tet-on-MC/9  NWPhWVVWSXCxcITvd4l{KEG|c3H5 MWexNE01OM7:TR?= M17TclEzcA>? NUnTRZRz[XS2ZX71ZZRmeyC2aHWgZ4VtdCCmZXH0bEBk[XW|ZXSgZpkhS0GSUz3hd5Nw[2mjdHXkJG5NWlB|IH31eIFvfHNiaX6geIhmKFSndD3vckB{gXO2ZX2= NHjwUZAzOzdyM{O4PS=>
KNS42  M4fGe2Fxd3C2b4Ppd{BCe3OjeR?= MV:1NO69VQ>? MkXFNYg> NXzSUJB5emWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36= MlTINlM3QTFzNEW=
MCF-7  M1LZSmFxd3C2b4Ppd{BCe3OjeR?= MUeyNO69VcLi MkPFO|Jp MYnpcohq[mm2czDldZVwdC1iYX7kJFQuV0iWLX3l[IlifGWmIHHwc5B1d3Orcx?= NGD3VY0zOzZ5NU[0Ny=>
hCMEC/D3  MX7BdI9xfG:|aYOgRZN{[Xl? NYnLXIxsOjYQvF2= MX:3Nog> NV7zdFM5emWmdXPld{BNfHiDIHnu[JVk\WRiYYDvdJRwe2m| MUeyN|Y3PTF7OB?=
Jurkat M1m2b2Fxd3C2b4Ppd{BCe3OjeR?= NYf2Z|Y3OTJwNT21NO69VQ>? NHO4UVIycA>? MYLkc5NmKGSncHXu[IVvfGy7IIP1dJBz\XO|ZYOgV3BJNWmwZIXj[YQhWGG{LUSgZ4xm[X[jZ3WsJHBCWlBiY3zlZZZi\2VuIFTORUBnemGpbXXueIF1cW:wLDDhcoQhdG:|czDv[kB3cWGkaXzpeJk> NG\C[mczOzR2Mkm3Oi=>
CNE-1 Ml;jRZBweHSxc3nzJGF{e2G7 NFTZb3kzOM7:TdMg M2XDSVI1cA>? M4Pqb4lvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi= NF;5W5AzOzR{Nki1NC=>
HONE-1 NYHENmhySXCxcITvd4l{KEG|c3H5 M33WRVIx|ryPwrC= NY\ReHJXOjSq NGfLTIlqdmirYnn0d{BTSURyMEGtbY5lfWOnZDDj[YxtKGSnYYTo NVzGdmZ[OjN2Mk[4OVA>
astrocytes cell MWPBdI9xfG:|aYOgRZN{[Xl? Ml7SOFDPxE1? NV35[2lqPmh? NFPkNldz\WS3Y3XzJIViemy7IHHwc5B1d3OrczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmV? MUmyN|QyOTd5OB?=
U-937 NV:1O|lwSXCxcITvd4l{KEG|c3H5 NF\6XW0yOM7:TR?= NUTUdIpPOzCvaX6= M4XNb5Bz\X[nboTzJHRPTi2rbnT1Z4VlKG6nY4LvdJRwe2m| MYSyN|QyODd2OB?=
MDA-MB-231 MmjXRZBweHSxc3nzJGF{e2G7 MVGxNFDPxE1? NWPsUGt[OWh? NUjLW3dbcW6qaXLpeJMhe2Wwc3n0bZpifGmxbjD0c{BVWkGLTDD1dI9vKE2WRFig[I94di2{ZXf1cIF1cW:w M1jyT|I{PDB6NEK5
HeLa  MmXjRZBweHSxc3nzJGF{e2G7 NWnWVoluOTByzszN NUizXlZ[Omh? NFfhN4JjdG:la4OgTnJUNTF3IFnu[JVk\XNiQYDvdJRwfGmlIFPlcIwhTGWjdHi= M1LkcVI{OzR2MES1
Ec109 MkfhRZBweHSxc3nzJGF{e2G7 M2TybVEx|ryP NF;veWw3cA>? NVfnRW1m[myxY3vzJIFxd3C2b4TpZ{Bkd22kaX7heIlwdiCxZjDUZZQuW22jY163JIFv\CC{YXTpZZRqd25? MXuyN|M{QDV4OB?=
H460  MlXjRZBweHSxc3nzJGF{e2G7 M{\wUFEx|ryP MoPjOog> MV3icI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=> NE[1OHkzOzN|OEW2PC=>
HeLa  MkDXRZBweHSxc3nzJGF{e2G7 NE\KOng2OM7:TR?= Ml32NU42cA>? NHXuSXZi[nKxZ3H0[ZPDqEOqbHHtfYRq[S2rbnT1Z4VlKGGyb4D0c5Nqew>? NIXhbm0zOzNyM{iwOC=>
SK-HEP1 MV\BdI9xfG:|aYOgRZN{[Xl? NF\SclkyODEQvF2= NI\qOpMycA>? MXfpcohq[mm2czDDdnQyKGGldHn2ZZRm\CClYYPwZZNmNTNuID23MEAuQCxiLUmsJIFv\CCyb3z5LGFFWC2{aXLvd4UqKHCxbInt[ZJie2V? MkTkNlM{ODJ4NUC=
QGY7701 M{fLXWFxd3C2b4Ppd{BCe3OjeR?= MVGyOe69VQ>? NIX3WYQyNjWq NHrV[oFqdmirYnn0d{Bi[2O3bYXsZZRqd25ib3[gd5VjNUdzIIDoZZNmKGmwZIXj[YQh[nliRF;YJEsheXWncnPleIlv MoT6NlMzPDByNkG=
HepG2 NXPwWo53SXCxcITvd4l{KEG|c3H5 MoTBNlDPxE1? MmrVN|BucW5? M2XmZolvcGmkaYTzJJRp\SCnbnjhcoNm\CClZXzsJIRm[XSqIHL5JINwdWKrbnXkJJRz\WG2bXXueEBw\iCjcHnn[Y5qdiCjbnSgWHJCUUx? MYeyN|IzPDJ|OR?=
U87  Mn\yRZBweHSxc3nzJGF{e2G7 NHHC[FUzPc7:TR?= NEOySoszcA>? M1\jNYRm[3KnYYPld{Bqe2:uaYH1bZJqfGmpZX7pckApUVOOKT3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYToMEBjfXRibn;0JI5m[3KxdHnjJINmdGxiZHXheIg> Mor3NlMzOjl4Mk[=
HSC-2 NEKx[FVCeG:ydH;zbZMhSXO|YYm= M2T1SlI2NzVyzszN M1W0S|Fp Mn\ybY5pcWKrdIOgV24uOzhvaX7keYNm\CCleYTveI95cWOrdIm= MnjSNlMyPTV{NEi=
HSC-4 M1fKO2Fxd3C2b4Ppd{BCe3OjeR?= MXyyOU82OM7:TR?= NG\s[ZIycA>? NYrQdWFocW6qaXLpeJMhW05vM{itbY5lfWOnZDDjfZRwfG:6aXPpeJk> M3HPR|I{OTV3MkS4
CL-1 MnTrRZBweHSxc3nzJGF{e2G7 NYD3bIxEOjEQvF2= NHHzU2IycA>? NWPreIRb[myxY3vzJG9RPDR7IHnu[JVk\WRiY3XscEBl\WG2aB?= MV6yN|E{OTd6Mh?=
MEL NWm5VXRzSXCxcITvd4l{KEG|c3H5 NF[4NlYzOM7:TR?= NGjwSGEzPGh? MX\EUXNQ M1LGeolueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN? MorzNlMxOTR6OEe=
Bel-7402  MVnDZZNx[XOnIFHjeIl3[XSrb36gRZN{[Xl? NV7ObJVsPTEQvF2= NGj1XGYzcA>? NXO1TnVycW6qaXLpeJMhWEOHLXnu[JVk\WRiYX7vbYtqew>? NUHxVmdkOjNyMEi3OFI>
Eca-109 M1WweWFxd3C2b4Ppd{BCe3OjeR?= MmK3NlXPxE1? MX2zNI1qdg>? MkftbY5pcWKrdIOgRmouSjFzLXnu[JVk\WRiY3XscEBl\WG2aB?= MnL2NlMxPzZ7Nke=
MEL MU\BdI9xfG:|aYOgRZN{[Xl? MV6yNO69VQ>? M3jqZVFp MY\EUXNQ MYXpcZBicXKnczDQNng4NWmwZIXj[YQhVUWOIHPlcIwh[XCxcITvd4l{ MV[yN|AyPDh6Nx?=
Bel-7402  M2fDfGFxd3C2b4Ppd{BCe3OjeR?= NVvjXIhDPTEQvF2= MUeybC=> M3TqXYlvcGmkaYTzJHBETS2rbnT1Z4VlKGGwb3nrbZM> MWeyN|AxQDd2Mh?=
L929 M{\zO2Z2dmO2aX;uJGF{e2G7 MXOyMlXPxE1? M3\meVFp MXHpcoNz\WG|ZYOgVmlROSCneIDy[ZN{cW:wIHHu[EBmgGGlZYLiZZRm\CCWTldOtU1qdmS3Y3XkJI1qfG:laH;u[JJq[WxiZInz[pVv[3Srb36gZY5lKFKRUzDwdo9lfWO2aX;u M1\MeFI{ODByNUG4
RCC  MnfxR4VtdCCYaXHibYxqfHliQYPzZZk> M4\jPVExOM7:TR?= MXOyOIg> M2fORZJm[2:4ZYLld{B1cGVidnnhZoltcXS7IH;mJINmdGy|IHX4dI9{\WRidH:gNVVlNVCJSkK= M3:wfFIzQTlzNEm0
NB2a/d1 Mne2RZBweHSxc3nzJGF{e2G7 M2PPUFExOM7:TR?= NEG4cmo4Omh? MXjheJRmdnWjdHXzJJN1[XW{b4Pwc5JqdmVvaX7keYNm\CClYYPwZZNmKGGldHn2bZR6NCCSQWLQMEBidmRidHH1JINt\WG4YXfl MoHtNlI6QDh3NEG=
T cell MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXiyOU0yODEQvF2= MVqyOIg> NILudHZld3OnLXTldIVv\GWwdHz5JIlvcGmkaYTl[EBVKGOnbHygdJJwdGmoZYLheIlwdiCvZXTpZZRm\CC2aILveYdpKHSqZTDjc{1{fGmvdXzheIlwdiC5aYToJIFvfGlvQ1SzJIFv\CCjboTpMWNFOjh? NF\Bc48zOjl6MkWzPC=>
K562 M3O4N2Fxd3C2b4Ppd{BCe3OjeR?= MWixNFDPxE1? NEfsSlYycA>? MmG4Zoxw[2u|IFHico9j[X[rc3P1ceKhTi2rbnT1Z4VlKGGyb4D0c5Nqew>? MYGyNlk4OjN5Mh?=
Jurkat  MlrYRZBweHSxc3nzJGF{e2G7 NVHU[Ho4PDEQvF2= NHnvV2EycA>? Mn;2ZYJwdGm|aHXzJGZie0xvaX7keYNm\CClYYPwZZNmKGGldHn2ZZRqd25iYX7kJINmdGxiZHXheIg> NEn5dJUzOjl2MkezPC=>
BGC-823 NGXneYpCeG:ydH;zbZMhSXO|YYm= NX;UWZp7OTByzszN MoX6NYg> NF;v[Jdx[XK2aXHscJkhemW|Y4Xld{Bk\WyuczDh[4FqdnO2IHThcYFo\SCxZjDkZYllgmWrbh?= Mki2NlI6OjZ3NEW=
Hep3B MYfBdI9xfG:|aYOgRZN{[Xl? NVrSXIQyPTEQvF2= NH60OFcycA>? Ml;JZoxw[2u|IHHwc5B1d3OrczDpcoR2[2WmIHL5JGhGT0O| NYfhc2VwOjJ7MkOxOVQ>
LLC-PK1 MUfBdI9xfG:|aYOgRZN{[Xl? MX6yNO69VQ>? M3LjOVFp NVPmS|FxeHKndnXueJMh[2m|cHzheIlvNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gRZRoPSxiYnXjcIlvNTFuIHHu[EBCfGdzMjDwdo91\Wmwcx?= MkjxNlI5QTZyM{e=
A549 NWO3Z|k2SXCxcITvd4l{KEG|c3H5 M4LXXlUx|ryP Mn\WNYg> M3;nPIJtd2OtczD0bIUhSkGLLXnu[JVk\WRiYYDvdJRwe2m|wrC= M3u1UVIzQDh5MkG1
SGC-7901  Mnf3RZBweHSxc3nzJGF{e2G7 MYSxNO69VQ>? NXS2bJVoOjSq NWDrcYttcW6qaXLpeJMh|rJuzsKt[Ilu\XSqeXzhZ5J6dHOqaXvvcolvNWmwZIXj[YQh[XCxcITvd4l{yqB? NFiybJQzOjh2OEW5Oy=>
DM6 NV7sVIZnSXCxcITvd4l{KEG|c3H5 NXPTcWZrOTByzszN MoXXO|Jp M{f0ZoJtd2OtczDic5RpKEV{Rj2xJIFv\CCHMl\0dk1u\WSrYYTl[EBkgXSxdH;4bYNqfHl? MVqyNlgzPTN{OB?=
MCF-7, MDA-MB-468, Caco-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlOVDPxE1? M{D3WFQ5cA>? NFTnSGtqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBqdmS3Y3XkJIJ6KHOjcH;ubY4> NW\NXGY4OjJ6MEC5Olg>
A2750  MXrBdI9xfG:|aYOgRZN{[Xl? NUnWR|d{OjEQvF2= NE\LOY4zcA>? MULEUXNQ MUPicI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg> MX2yNlc5PDN4Mx?=
U87  NGPtSnpCeG:ydH;zbZMhSXO|YYm= MXKyNO69VQ>? MVqyOIg> MX;y[YR2[2W|IITo[UBieG:ydH;zbZMhemG2ZTDpcoR2[2WmIHL5JHBNSUJ? NWPiWGtvOjJ5N{i3PFA>
HT1080 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3DOVDPxE1? MlXJO4Q> M{W5NIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJINifXOnZDDifUBkd22kaX7l[EB1emWjdH3lcpQhd2ZiRFPBJIFv\CCRTWC= MoHjNlI4PDB7OES=
A549  NVn3SnlJSXCxcITvd4l{KEG|c3H5 NX32dFVDPTEQvF2= NIXUbJkzcA>? NWHKcYFOeGG{dHnhcIx6KGSnY4LlZZNmeyC|b3TpeY0he2WuZX7peIUucW6mdXPl[EBieG:ydH;zbZM> NHPMTHQzOjd{MUiwOC=>
Primary OPC Mn3iRZBweHSxc3nzJGF{e2G7 NInvdIMy|ryP M4DQWFZpNzJ2aB?= M3zxRpJm\HWlZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6g[YFzdHlvIHHu[EBt[XSnLXHwc5B1d3Orcz;u[YNzd3Orcx?= NFvzRo4zOjdyN{O4OS=>
PMNs NXHadZVvSXCxcITvd4l{KEG|c3H5 NGjZW2w1OM7:TR?= MYK2bC=> M1zodmROW09? NEfJfYFz\X[ncoPl[EB1cGViYX3veY51KG:oIHPs[YF3\WRiY3HzdIF{\S1|IITvJI5m[XJidnXobYNt\SCuZY\lcJM> MnfiNlI3QTJ3N{e=
A549  M3n4UGFxd3C2b4Ppd{BCe3OjeR?= MlXHOVDPxE1? NXjxTFR{OWh? Mm\kdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSmGxaIXvd4ll\SCL NX7o[4NqOjJ4OEe2N|U>
AGS NYq2VXpqSXCxcITvd4l{KEG|c3H5 NXvablVNOjEQvF2= M3fiUlEzcA>? MUTpcohq[mm2czD0bIUh[WO2aY\heIlwdiCxZjDwdo8u[2G|cHHz[U0{KGmwIILld5BwdnOnIITvJJRp\SCHdF;BZ{BnemGldHnvci=> M1rOSVIzPjh5M{m4
shC9  NXHyfnZDSXCxcITvd4l{KEG|c3H5 MXmxNO69VQ>? NVfod3JqOT[q NEjjOWhjdHWwdIOgV2hJKGW6cILld5Nqd25iaX6gd4hEQSClZXzsd{BmgHCxc3XkJJRwKGWrdHjldkBRSSCxcjDMVGM> NELBNmkzOjZ2MUC5OC=>
primary MEFs NUnOO5ZwTnWwY4Tpc44hSXO|YYm= NHe0fGkyOmh? MoXHxsBqdmO{ZXHz[ZMh\XSxcH;zbYRmNWmwZIXj[YQhdWm2b3Poc45lemmjbDDt[Y1jemGwZTDk[ZBwdGG{aYrheIlwdg>? NI\4S5UzOjZzM{e2Oy=>
3T9 MEFs MVzGeY5kfGmxbjDBd5NigQ>? NFzDXXcyPmh? M{jieIlv[3KnYYPld{BkgXSxY3jyc41mKGNicnXs[YF{\SCjZoTldkBmfG:yb4Pp[IUufHKnYYTt[Y51 MUmyNlYyOzd4Nx?=
3T9 MEFs M3HZVmZ2dmO2aX;uJGF{e2G7 M{LZVVE5cA>? NXnNRXVjfXC{ZXf1cIF1\XNiaX7peIlifG:{IHPhd5Bie2VvOTDieZQh\G:5boLl[5Vt[XSnczDl[oZm[3SxcjDjZZNx[XOnczDh[pRmeiCndH;wc5Nq\GVidILlZZRu\W62 M3zBfVIzPjF|N{[3
MDA-MB-231  NVWzVVJ[SXCxcITvd4l{KEG|c3H5 MmTiNlDPxE1? NIPK[JA1\A>? M1HVOZJm\HWlZYOgeIhmKGOnbHygZZBweHSxc3nzJIlv\HWlZXSgZpkhdWW2Zn;ycYlvKHS{ZXH0cYVvfCC5YYOgd4lodmmoaXPhcpRtgQ>? NHXjOJIzOjV7M{S0NS=>
C6  MVfBdI9xfG:|aYOgRZN{[Xl? M2mxTFEx|ryP MYmyOIg> M4r0OIJtd2OtczD0bIUhe3WycILld5NqfmViZX\m[YN1KG:oIITo[UBx\XC2aXTlJI9vKH[rYXLpcIl1gQ>? NV7QSVBYOjJ3OEi5PFA>
HL-60  MlTRRZBweHSxc3nzJGF{e2G7 NI[xNpIyODEQvF2= NHLjZZYzPGh? NFPhZlJqdmirYnn0d{B1cGViY3XscEBieG:ydH;zbZMhe2WuZXP0[YQhMCtrLX3lcpRpgWxizsKtLFHjjpJ4KT3kbYdtfWOxcInyZY5we2mmZdMgOS=> MUeyNlU1PjZ4OR?=
HL-60 MWXBdI9xfG:|aYOgRZN{[Xl? MUexNE05OM7:TR?= NVvCXVJEPGh? MmrVbY5pcWKrdIOgWGdJWS2rbnT1Z4VlKGOnbHygZZBweHSxc3nzxsA> MYeyNlUzOzJ{OR?=
BCC NWSwSXNUSXCxcITvd4l{KEG|c3H5 MWG1NO69VQ>? MUWxbC=> MlvJbY5pcWKrdIOgSGFVWy2vZXTpZZRm\CCpcn;3eIghcW6qaXLpeIlwdg>? M4PFTVIzPTF7NEO2
RAW 264.7 M{LNZmFxd3C2b4Ppd{BCe3OjeR?= NUTZWlJZPTBxMUCw{txO NWrMZ4JvOWh? MlrSZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfHNiRF;OMYlv\HWlZXSgdnJPSSClbHXheoFo\Q>? NXy1VpVpOjJ2OUG0NlY>
K562 NELuOWRCeG:ydH;zbZMhSXO|YYm= MmjzNlXPxE1? NVrzcm1tOmh? M3vybZBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?= NUi1e4p{OjJ2OEO3O|c>
SGC-7901 MWPBdI9xfG:|aYOgRZN{[Xl? NFntRmszOCEQvF5CpC=> M1LjSlJp MmLWZZR1\W63YYTld{BJOk9{wrDvdkBVVkZizsGtbY5lfWOnZDDj[YxtKGGyb4D0c5NqeyCjczD3[YxtKGG|IHPhd5Bie2VvMzDhZ5Rqfmm2edMg NX[yWW5xOjJ2N{G1PFk>
PC3 NFLsdWRCeG:ydH;zbZMhSXO|YYm= NE\IXWwyOM7:TR?= NV3xVnptPGh? NXrXO|BL[2:3boTldpMh\myjdn;jc5hq\C2rbnT1Z4VlKGOjc4Dhd4UuemWuYYTl[EBieG:ydH;zbZM> NU\BbnNuOjJ2N{G5O|Q>
SMMC-7721 NEnTUnFCeG:ydH;zbZMhSXO|YYm= NUfrZWZjPTEQvF2= M{Dib|Q5cA>? NYf2bG1t[XS2ZX71ZZRmeyCxVGKtbY5lfWOnZDDhdI9xfG:|aYO= MXeyNlQ3PTh|Mx?=
HeLa  MUDBdI9xfG:|aYOgRZN{[Xl? M1XuUFUxyqEQvF2= MV:0M|hp NEC3bohqdmirYnn0d{BUXFNvaX7keYNm\CCuYYTlMZBp[XOnIHHwc5B1d3SrYzDleoVvfHN? MmrGNlI1PjB3MES=
HeLa  NGnjNIVCeG:ydH;zbZMhSXO|YYm= NELLWJU2OMLizszN M2fvWVFp NHfDVG5{fXCycnXzd4V{KHSqZTDGVmFRNWmwZIXj[YQh[WOldX31cIF1cW:wIH;mJIFvdmW6aX6gWkBxd3OrdHn2[UBk\Wyucx?= MoTuNlI1PDl2NEC=
T47D  M3LWc2Fxd3C2b4Ppd{BCe3OjeR?= MUexNFDPxE1? NFr1d2oycA>? NInVRWNjdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO= NEW4U3ozOjRyMUG2PC=>
HeLa  NIq5U|lCeG:ydH;zbZMhSXO|YYm= M3ni[VMx|ryP NEjnXGw1cA>? MnTQxsBqdmO{ZXHz[ZMhfGinIHflcoVz[WxiY3XscEB3cWGkaXzpeJkhPDhiaDDh[pRmeiCyaH;0c4R6dmGvaXOgeJJm[XSvZX70xsA> M1\NTFIzOzl2MkS4
HCC NHH4O2tCeG:ydH;zbZMhSXO|YYm= MkfiNlAh|ryPwrC= MmfyNog> M1LzZ4F1fGWwdXH0[ZMhfGinIFTIRUBqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiUFHSVC=> M3PrcVIzOzR{N{Oy
mESCs MmPvRZBweHSxc3nzJGF{e2G7 M3LmNVIvPc7:TR?= NHThWm8zcA>? NX\USW5WcW6qaXLpeJMhfGinIF7hSk1u\WSrYYTl[EBk[XOyYYPlJIFkfGm4YYTpc44> M4rnWVIzOjh3Mke0
EMT-6  NUnHfoJxS3m2b4TvfIlkcXS7IFHzd4F6 NHXlTYwyODEQvF2= Mnr4NYg> NXHhSIZleGG{dHnhcIx6KGKub3Pr[YQh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IIPpdoFu\XOrbnW= NHj5O2EzOjJ3MUmyNS=>
MCF7 MUXBdI9xfG:|aYOgRZN{[Xl? MmLxOVDDqM7:TR?= M2j2d|Fp NVfhNoNtcW6qaXLpeJMhWEFiYXP0bZZifGWmIHPhd5Bie2VvMzygMVktKGGwZDDwc4x6MEGGUD3ybYJwe2VrIIDvcJlu\XKjc3W= MYmyNlIzOzN2NR?=
K562 Mn3YRZBweHSxc3nzJGF{e2G7 NIPwXVQzOCEQvF5CpC=> MV20PIg> MkC3SG1UVw>? Mmf3Zoxw[2u|IHzhdIF1cW6rYj3pcoR2[2WmIHnubIljcXSrb36gc4YhfmmjYnnsbZR6KGGwZDDhdI9xfG:|aYOgbY5lfWO2aX;u MlHlNlIzOTZzNUi=
Molt4-hyg MV\BdI9xfG:|aYOgRZN{[Xl? M{\4UlEx|ryP MXWwMlVp NFG1VpVjdG:la4Og[oFzdmW|b3ytbY5lfWOnZDDjZZNx[XOnLUOtcIls\SCjY4Tpeol1gQ>? NYfVcXd2OjZ{N{W4NVE>
HeLa NIHifpJCeG:ydH;zbZMhSXO|YYm= M3fFV|Ex|ryP MnLUNE42cA>? M3PJWIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KHSqZTDjc41jcW6nZDD0doVifG2nboSge4l1cCCpb33pd4lvKE5iYX7kJHRTSUmO NUnJRZpsOjJzN{m2OlE>
Jurkat T MoPCRZBweHSxc3nzJGF{e2G7 NGrSSI0{OM7:TR?= NFmzOooxNjWq NYTpSGdPTE2VTx?= NGX1fmpjdG:la4OgeIhmKHqrcnHtMYlv\HWlZXSgZZBweHSxc3nz MWWyNlE2QTh7OB?=
Neutrophil NVfNfo5ySXCxcITvd4l{KEG|c3H5 Mn3XNlDPxE1? MXiwMlVp NIG5[41ifHSnboXheIV{KHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeEBw\iCPYWKx MWKyOlE6Pjh2NB?=
HCT116 M4i1[mFxd3C2b4Ppd{BCe3OjeR?= MUe1NOKh|ryP NESxWnozcA>? NH7VXo9z\X[ncoPld{B{gW6ncnfpd5Rq[yCjcH;weI9{cXNiZX\m[YN1eyCxZjDj[Yxm[2:6aXKgZY5lKE6SQz2xOuKh NHK0UI8zOjF3OUe1Ni=>
MDA-MB-231  NEHpWZJCeG:ydH;zbZMhSXO|YYm= MXqyMlUuPy53zszN MV:ybC=> Mn7RbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhib3[gUWRCNU2ELUKzNUBk\WyuczDpcoR2[2WmIHL5JHNFXCCrbjDhJINwdmOnboTyZZRqd25iZHXw[Y5l\W62IH3hco5meg>? NIrYUVgzOjFzNUWyOi=>
LNCaP NEjTSG9CeG:ydH;zbZMhSXO|YYm= NWrTVY43PDEQvF2= MWWybC=> NHqycW1qdmirYnn0d{BjfXSnaX6gbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>? MmG5NlIyOTR5NkS=
MB231 MYDBdI9xfG:|aYOgRZN{[Xl? MlLsNVAx|ryP MmPENYg> M33JUmROW09? MWThZpJw\2G2ZYOgeIhmKGmwZIXjeIlwdiCxZjDj[YxtKGSnYYToJIJ6KFeHRUGgbY5pcWKrdHnvckwhXFKDSVygeJJm[XSvZX70MEBidmRidHjlJINwdWKrbnH0bY9v M1LrbFIzOTF{OUSw
HCC38  NXznSWZPSXCxcITvd4l{KEG|c3H5 M36x[|ExOM7:TR?= NFrqUGMycA>? NF\XfXFFVVOR NI\MdoVi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:w MYiyNlEyOjl2MB?=
MDA-MB231 NVTGSYw6SXCxcITvd4l{KEG|c3H5 M17qTVUxyqEQvF2= NFi2W2QzPGh? M{XlR2ROW09? NIHlWHdi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRp NFzLRZUzOjFyMUOzOS=>
LNCaP Ml3wRZBweHSxc3nzJGF{e2G7 NInMOHU2OMLizszN NEfRNXMzPGh? MmW4SG1UVw>? MVjhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYTo MkmyNlIyODF|M{W=
HCT116 M13FS2Fxd3C2b4Ppd{BCe3OjeR?= MV21NOKh|ryP NHvQeo0zPGh? M{PBSWROW09? M3rCeoFjem:pYYTld{BkfXKldX3pck1qdmS3Y3XkJINmdGxiZHXheIg> MUSyNlExOTN|NR?=
Ishikawa  NGDZbWlCeG:ydH;zbZMhSXO|YYm= NWjTWWw6OjYQvF2= NVTydZh4OjSq MofrdoVlfWOnczDj[YxtKGSnYYToJIFv\CCjcH;weI9{cXNiaX7keYNm\CCkeTDCZYYhSTF? M{DSdVIzODh6OUG4
 YD-8  Mn\DRZBweHSxc3nzJGF{e2G7 MXyxNFDPxE1? NV2zN4RvOWh? MkjybY5pcWKrdIOgVGxGVy2rbnT1Z4VlKGGyb4D0c5Nqew>? NIHrbHQzOjB6NkG4Ny=>
eosinophil  MoT4RZBweHSxc3nzJGF{e2G7 MXe5NO69VQ>? NX;Y[2FsOjSq MlX3bY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhTmG|IHHueIljd2S7wrC= M3HRTlIzODd7M{O0
L929 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCwNk42|ryP M{\odFI1cA>? NYPobGlNcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YheC2yM{igZY5lKE6ILd86RkB1dyCjdXft[Y51KFSQRt8xMYlv\HWlZXSgcoVkem:ydH;zbZMh[W6mIHH1eI9xcGGpeR?= MlHnNlIxOjdyOUe=
YD-8  NH3DXpZCeG:ydH;zbZMhSXO|YYm= M3vmb|ExOM7:TR?= MljlNYg> MlvPZoxw[2u|IITo[UBIWy2KQ3ytbY5lfWOnZDDhdI9xfG:|aYO= MnzUNlIxOjByN{i=
HBx M3LCZmFxd3C2b4Ppd{BCe3OjeR?= NY\vb3dHOjYQvF2= MVG0PIg> NGTUN2dFVVOR MXry[YR2[2WmIHPlcIwh\GWjdHigbY5lfWOnZDDifUA{NU2D MoDXNlIxOjByN{i=
U937  M3fPT2Fxd3C2b4Ppd{BCe3OjeR?= NX7ONIJxPTEEoN88US=> Ml\NNYg> NYflZ|hFcW6qaXLpeJMhUEZvaX7keYNm\CCjcH;weI9{cXQEoB?= NEPKT28zOTl7OEezNS=>
HL60 NX30ZlIySXCxcITvd4l{KEG|c3H5 M2jzUVQx|ryP M3nleVQxdWmw M1LmfGROW09? M13yZYJtd2OtczDCUmREKGOxbYDveY5leyCrbnT1Z4Uh\Xiyb4P1doUhd2ZicHjvd5Bp[XSrZInsd4VzcW6nIHHu[EBFVkFiZoLh[41mdnSjdHnvci=> M{f2c|IyQTh|Mkm2
M-14 MWTBdI9xfG:|aYOgRZN{[Xl? M{LQeFI2|ryP M{DyZ|AvPWh? MWZCpIlvcGmkaYTzJIJwfGhidHjlJINzfWSnIHX4eJJi[3RvIHHu[EBkd22yb4Xu[E1qdmS3Y3XkJIFxd3C2b4Ppdy=> M4X4UlIyQTV2OUW5
SK-BR-3 MlrrRZBweHSxc3nzJGF{e2G7 MV61NOKh|ryP NIjrXm0zcA>? NGS5UGhjdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> NEDFfmYzOTlyMUO4Oi=>
MDA-MB-468 NETH[nhCeG:ydH;zbZMhSXO|YYm= MVK1NOKh|ryP MYeybC=> NH61dHljdG:la4OgZZBweHSxdHnjJGRPSSCocnHncYVvfGG2aX;uJIlv\HWlZXSgZpkh[2:vYnnuZZRqd25ib3[gV20uOTZ2IHHu[EBz[WSrYYTpc44> M3fQ[VIyQTBzM{i2

... Click to View More Cell Line Experimental Data

In vivo In vivo Z-VAD-FMK administration has been shown previously to be nontoxic and to prevent apoptosis in animal models. Intraperitoneal HK-GBS injection leads to preterm delivery, and pretreatment with Z-VAD-FMK delays preterm delivery in mice. In OVA-sensitized mice,treatment of z-VAD-fmk inhibits allergen-induced leukocyte infiltration. Systemic injection of the pan-caspase inhibitor z-VAD-fmk immediately before OVA challenge reduced inflammatory cell accumulation, mucus hypersecretion, and Th2 cytokine release in OVA-sensitized/challenged mice. Treatment with z-VAD-fmk blocked terminal differentiation of lens epithelial cells and keratinocytes, the differentiation of monocytes into macrophages, and the differentiation of erythroid progenitors. z-VAD-fmk attenuated allergen-induced airway inflammation and hyperreactivity. Treatment with z-VAD-fmk in vivo also prevented subsequent T cell activation ex vivo[7].

Protocol

Cell Research:

[6]

+ Expand
  • Cell lines: human granulosa cell lines (GC1a, HGL5, COV434)
  • Concentrations: 50 μM
  • Incubation Time: 48 h
  • Method:

    To validate the efficacy of Z-VAD-FMK, three human granulosa cell lines (GC1a, HGL5, COV434) were treated for 48 h with etoposide (50 μg/ml) and/or Z-VAD-FMK (50 μM) under normoxic conditions. To mimic the ischemic phase that occurs after ovarian fragment transplantation, cells were cultured without serum under hypoxia (1 % O2) and treated with Z-VAD-FMK. The metabolic activity of the cells was evaluated by WST-1 assay. Cell viability was determined by FACS analyses. The expression of apoptosis-related molecules was assessed by RT-qPCR and Western blot analyses.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD1 mice
  • Formulation: dissolved in DMSO, diluted in PBS (final concentration of DMSO < 1%)
  • Dosages: 10 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

DMF 84mg/ml

Chemical Information

Molecular Weight 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you suggest an in vivo formulation of S7023 for animal studies?

  • Answer:

    For in vivo study of S7023, The IP formulation is 2% DMSO+35 % PEG 300+2% Tween 80+ddH2O up to 6 mg/ml. The gavage formula is 1%CMC-Na up to 30 mg/ml (suspensions).

  • Question 2:

    What is difference between S7023 & S8102?

  • Answer:

    Unlike S7023, S8102 does not require pretreatment with esterase for in vitro studies. This information was cited from the article: https://www.ncbi.nlm.nih.gov/pubmed/16973565.

Caspase Signaling Pathway Map

Related Caspase Products

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID